NABOTA

Live / Registered — Registered (as of 15 Jun 2021)

What this means for you

Registered since 15 Jun 2021. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
88938201
Registration number
6383994
Mark type
Stylized text
Filed
28 May 2020
Published for opposition
30 Mar 2021
Registered
15 Jun 2021
Attorney of record
John M. Kim

Goods and services

  • Class 005 — Pharmaceuticals: Botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction and pelvic pain; Pharmaceutical preparations, namely, acne medications, acne treatment preparations, adrenal hormone preparations, alcohol for topical use, allergy and allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretics, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, chemical compounds for drug delivery, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, vaccine adjuvants, vaccine stabilizers, diuretics, amino acids for medical purposes; Medicines for the treatment of gastrointestinal diseases; chemical preparations for pharmaceutical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; chemico-pharmaceutical preparations for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain. drugs for medical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; Medicines for human purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; pharmaceutical preparations for activating cellular function; Adjuvants for medical purposes; pharmaceutical preparations for central nerve treatment, namely, for the treatment of sequelae caused by damage to the central nerve in the brain; dermatological pharmaceutical products, namely, injectable botulinum toxin for refining wrinkles; pharmaceutical preparations for treating skin disorders; antibiotic preparations; pharmaceutical preparations for chemical disorder treatment, namely, for treatment of chemical imbalance in the brain

Owner

Prosecution history

  • 15 Jun 2021 — REGISTERED-PRINCIPAL REGISTER
  • 30 Mar 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 30 Mar 2021 — PUBLISHED FOR OPPOSITION
  • 10 Mar 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 22 Feb 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 01 Feb 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 01 Feb 2021 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 27 Jan 2021 — ASSIGNED TO LIE
  • 15 Oct 2020 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 28 Aug 2020 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
  • 28 Aug 2020 — NON-FINAL ACTION E-MAILED
  • 28 Aug 2020 — NON-FINAL ACTION WRITTEN
  • 28 Aug 2020 — ASSIGNED TO EXAMINER
  • 17 Jun 2020 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
  • 01 Jun 2020 — NEW APPLICATION ENTERED

View this trademark record on Marksy